In this report, guidelines for the evaluation, medical and surgical management is presented. It is categorized according to the stage of the disease using the tumor node metastasis staging system, 7 th edition. The recommendations are presented with supporting level of evidence.
INTRODUCTION
A total of 1869 cases of prostate cancer were recorded in Saudi Arabia between the year 1994 and 2004. The number of cases has been increasing steadily from 151 in 1994 to a peak of 243 cases in 2004. [1] 
STAGING EVALUATION
Once diagnosis is confirmed, the following staging evaluation should be done: 1.1.
CT or MRI abdomen and pelvis: this will only be done when the chance of lymph node metastasis is more than 10% based on Partin predictive tables (EL-2). [2] [3] See Tables 1 and 2  1. 2.
Bone scan: should be done if any of the following (EL-2): [4] [5] 1.2.1. PSA level more than 20 1.2.2.
Patients with bony pain 1.2.3.
Gleason score more than 7 1.2.4.
Patient with clinical stage T3 or 4
STAGING CLASSIFICATION
The TNM staging will be used [6] Primary tumor (T)
TX
Tumor cannot be assessed TO No evidence of primary tumor T1
Clinically not palpable or visible by imaging T1a
Found incidental to other surgery; present in 5% or less of tissue T1b
Found incidental to other surgery; present in 5% or more of tissue T1c
Identified by needle biopsy T2
Tumor confined within prostate T2a
Involving half a lobe or less of prostate T2b
Involving half a lobe T2c
Involving both lobes T3
Tumor extends through prostate capsule T3a
Extends through one lobe T3b
Extends through both lobes T3c
Extends into seminal vesicles T4
Involves structures other than seminal vesicles T4a
Invades bladder neck, external sphincter, or rectum T4b
Invades muscles and/or pelvic wall
Regional lymph nodes (N)

NX
Nodes cannot be assessed NO No regional node metastasis N1 Single node metastasis, 2 centimeters (cm) or less at largest point less than 5 years: no further intervention required until he becomes symptomatic. [8] [9] [10] (EL-2) 3.1.1.2.
If asymptomatic with life expectancy between 5 and 10 years: active surveillance (involves active monitoring of the course of disease with the expectation to intervene if the cancer progresses). [8] [9] [10] (EL-2) 3.1.1.3.
If asymptomatic with life expectancy more than 10 years: options include active surveillance [10] or radical prostatectomy (RP) [11] or EBRT. [12] (EL-2) 3.1.1.4.
All RPs should be done in tertiary care centers by high-volume surgeons. [13] (EL-2) 3.1.1.5.
Lymphadenectomy is usually omitted if the chance of being positive is less than 2%. [14] (EL-2) 3.1.1.6.
3D conformal EBRT or Intensity-modulated EBRT (IMRT) are the only acceptable form of radiation therapy. The minimum dose should be not less than 72 Gy. [12, [15] [16] [17] [18] [19] (EL-2) 3.1.1.7.
The choice of therapy should depend on the patient's general condition, his preference and side-effect profile. 3.1.2.
Intermediate risk: options of therapy depend on the following factors: 3.1.2.1.
If life expectancy less than 5 years: patient will have no further intervention until he becomes symptomatic. [8] [9] [10] (EL-2) 3.1.2.2.
If life expectancy between 5 and 10 years: options include active surveillance [10] or EBRT+ 6 months of androgen deprivation therapy (ADT) [12, 20] or RP. [11] (EL-2).
If life expectancy more than 10 years: Options are RP with extended lymphadenectomy [11, 21] (EL-1) or EBRT + 6 months of ADT (Radiation therapy to cover pelvic lymph nodes if chance of involvement is more than 15%). [12, [15] [16] (EL-2) 3.1.2.4.
Patients who have pT3 should undergo adjuvant EBRT to prostatic bed (66 Gy). [22] [23] [24] [25] [26] (EL-2) 3.1.2.5.
Patients who have positive margin following RP might undergo adjuvant EBRT to prostatic bed [22] [23] [24] [25] [26] or surveillance. [27] [28] (EL-2) 3.1.3.
High risk: Options include RP + extended lymphadenectomy [29] [30] (EL-3) or EBRT (to include pelvic lymph nodes) with 2-3 years of ADT. [31] [32] [33] [34] [35] [36] [37] (EL-1) Other site(s) involved
MANAGEMENT OPTIONS
This will depend on the stage (localized vs metastatic), the risk group and life expectancy. [7] 3.1. Localized disease 3.1.1.
Low risk: options of therapy depend on the following factors: 3.1.1.1.
If the patient is asymptomatic with life expectancy
Patients who have advanced local disease and are unfit for the above two options may be given ADT. [38] (EL-1) 3.1.4.
Follow up after curative therapy: Patients should have a disease-specific history, serum PSA and digital rectal examination (DRE) at 3, 6 and 12 months after therapy, then every 6 months for 3 years and then annually. [39] (EL-3) 3.1.5.
Management of recurrence post RP: 3.1.5.1.
Definition: recurrence post-radical prostatectomy is defined by PSA level more than 0.2 ng/dl. [40] [41] 3. [50] [51] [52] (EL-2). 3.1.6.
Management of local recurrence after EBRT 3.1.6.1.
Definition: a PSA rise 2 ng/mL above the PSA nadir is the most reliable indication for recurrence [53] [54] (EL-2). However local recurrence is defined by the presence of all of the following: [55] [56] 3.1.6.1. Options of therapy include: observation up to PSA of 10 ng/dl, complete androgen blockade, and intermittent androgen deprivation. [57] In carefully selected patients, salvage prostatectomy, cryosurgery and brachytherapy might be considered. [58] [59] [60] [61] 3.2.
Advanced disease (including recurrence and metastasis): 3.2.1.
Hormone responsive disease: 3.2.1.1.
ADT palliates symptoms and reduces the risk for potentially catastrophic sequelae of advanced disease (spinal cord compression, pathological fractures, ureteral obstruction, extraskeletal metastasis). [62] [63] [64] (EL-1) 3.2.1.2.
Options of therapy include: orchiectomy, LHRH agonists, anti-androgen monotherapy, and complete androgen blockade (CAB) continuous or intermittent. [62] [63] [64] 3.2.1.3. High-risk patients with high PSADT, high initial PSA and symptomatic patient should preferably receive combined androgen blockade, while patients with low initial PSA, low PSADT and minimal symptoms may receive castration alone. [65] [66] [67] [68] [69] [70] [71] [72] (EL-2) 3.2.1.4.
Castrate level of testosterone should be less than 20 ng/dl (0.7 nmol/L). [73] [74] 3.2.1.5. In case of intermittent androgen blockade (EL-2), the following should be observed: [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [95] (EL-2), Ketoconazole [94] (EL-2), systemic chemotherapy. 3.2.2.2.4. Systemic chemotherapy in the form of Docetaxel and prednisone should be offered only to patients with performance status 0-2 by ECOG scale. [96] [97] [98] (EL-1) 3.2.2.2.5. Patients with CRPC who were on LHRH agonists should continue on them indefinitely. [99] [100] [101] (EL-3) 3.2.2.2.6. Patients who fail Docetaxel-based chemotherapy should be offered second-line chemotherapy with Cabazitaxel and prednisone if in good performance status. [102] (EL-1) 3.2.2.2.7. Patients with advanced disease and bone metastatic should receive zoledronic acid [103] [104] [105] (EL-1) or Rank-ligand antibodies (Denosumab) therapy every 4 weeks. [106] (EL-1)
